Navigation Links
Arsenal Capital Partners Acquires Leading Model-Based Drug Development Company Certara
Date:12/19/2013

NEW YORK, Dec. 19, 2013 /PRNewswire/ -- Arsenal Capital Partners, a leading New York-based private equity firm that invests in middle market healthcare and specialty industrial companies, announced today the acquisition of Certara, the leading provider of model-based drug development and data analytics software and consulting services to the biopharmaceutical research and development market.Certara provides highly specialized and integrated solutions which consist of computer-based models supported by leading scientific consulting services and which span the discovery, pre-clinical and clinical stages of drug development. Certara's solutions provide clients with significant reductions in the time and expense of bringing new drugs to market by enabling data-driven decisions which lead to more precisely designed studies with less risk of failure and improved subject safety– a benefit in the highly-regulated and increasingly costly research and development environment.

Stephen McLean, a Partner at Arsenal and Co-Head of the firm's Healthcare Group, said, "We are delighted to invest in this exciting company which is making such an important contribution to improving the productivity of the drug development process. The average cost today of researching and developing a new drug is over $1.5 billion and takes 10-15 years. This is clearly inconsistent with the imperative of reducing the costs of global healthcare and Certara will make a difference."

Dr. James Rothman, a recipient of the 2013 Nobel Prize in Physiology or Medicine, who evaluated the Certara acquisition in his role in Arsenal Capital Partners' Healthcare Group, said Arsenal was interested in the acquisition because of Certara's ability to increase both the effectiveness and efficiency of the drug development process. "Model-based drug development is allowing pharmaceutic
'/>"/>

SOURCE Arsenal Capital Partners
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Soligenix Announces Initial $600,000 Investment and up to $10.6 Million Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC
2. UCLA Venture Capital Fund Selects KYTHERA Biopharmaceuticals CEO Keith Leonard for First Annual Entrepreneurial Achievement Award
3. TVM Capital Group Announces Two-pronged Global Investment Strategy with Renewed MENA Focus
4. Foundation Venture Capital Group Portfolio Company Identifies FRY Gene As Breast Cancer Susceptibility Suppressor
5. S&P Capital IQ to Share Its Views on the Biotech Bull Market During the Next "ETF Analyst Hour"
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. Regado Biosciences, Inc. to Present at Aegis Capital Vegas Healthcare Conference
8. GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
9. Capitalizing on Opportunities in Cord Blood Industry Growth (2013 Version)
10. RXi Pharmaceuticals Announces Application for NASDAQ Capital Market Listing and Reverse Stock Split
11. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... San Mateo, CA (PRWEB) July 14, 2014 ... groundbreaking CONNECT patient registry platform, announced that ... Becker muscular dystrophies; the Phelan-McDermid Syndrome International ... primary Nephrotic Syndrome—have been awarded contracts by ... part of the creation of a new ...
(Date:7/13/2014)... -- The discovery 30 years ago of soccer-ball-shaped carbon ... nanotechnology research. Now, there appears to be a new ... Shanxi University and Tsinghua University in China have shown ... hollow molecular cage similar to a carbon buckyball. It,s ... only a matter of speculationdoes indeed exist. , "This ...
(Date:7/13/2014)... 2014 Deep Research Report on Global and China ... on the current state of the Nano Silver industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
Breaking Biology Technology:PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3
... - Appointment Enhances Algeta,s Commercial Capabilities ... Cancer , Algeta ASA ... Kay has been appointed as President and Chief,Executive Officer and ... Thomas,Ramdahl will continue as Executive Vice President and Chief Technology,Officer ...
... TUSTIN, Calif., Dec. 11 Peregrine Pharmaceuticals, Inc. (Nasdaq: ... its Board of Directors, unexpectedly passed away on Wednesday. Dr. ... chairman since 2005. At the time of his death, Dr. ... , , "The sudden ...
... Alimera Sciences Inc., a privately held,biopharmaceutical company ... prescription ophthalmic pharmaceuticals, today reported,that enrollment has begun ... and efficacy,of Iluvien(TM) in patients with bilateral geographic ... The pilot ...
Cached Biology Technology:Algeta Appoints Andrew Kay as President and Chief Executive Officer 2Algeta Appoints Andrew Kay as President and Chief Executive Officer 3Algeta Appoints Andrew Kay as President and Chief Executive Officer 4Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz 2Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD 2
(Date:7/11/2014)... that cannabinoid receptor type 1 can inhibit ... and reduce neurotransmitter release. However, some scholars ... increase extracellular Ca2+ influx and increase neurotransmitter ... Tongji Hospital Affiliated to Tongji Medical College, ... used whole cell voltage-clamp and calcium imaging ...
(Date:7/11/2014)... of all vertebrates, information is transmitted through synapses, ... signal to be passed from one brain cell ... abundant type of synapse, can be either excitatory ... memory, perception and cognition, and the balance between ... For instance, every time we learn something, ...
(Date:7/10/2014)... NEW YORK , June 27, 2014 /PRNewswire/ ... against Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: ... action, filed in United States District Court, Middle ... Division, is on behalf of a class consisting ... otherwise acquired Provectus securities between December 17, 2013 ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... shellfish, snails and other animals from the Pacific Ocean ... was interrupted by cooling conditions three million years ago, ... of California, Davis, and Peter Roopnarine at the California ... ice-free Arctic Ocean by 2050. That will restore conditions ...
... Pharmacy researchers have discovered a marine compound off the ... in laboratory tests, a finding they hope will fuel ... disease. The UF-patented compound, largazole, is derived from ... results from early studies today (Aug. 7) at an ...
... The University of Houston department of health and human performance ... a study promoting healthy dietary habits and physical activity. ... of Second Life (SL). , ... is part of the UH Texas Obesity Research Center,s (TORC) ...
Cached Biology News:Pacific shellfish ready to invade Atlantic 2Researchers find cancer-inhibiting compound under the sea 2Researchers find cancer-inhibiting compound under the sea 3TORC at UH turns to virtual world of Second Life for new study 2
XEDAR Antibody...
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
Rabbit Anti-JNK1/SAPK pan, Polyclonal Antibody...
...
Biology Products: